Clinical trial approval: Pherecydes Pharma obtains ANSM Approval for its PhagoDAIR program, which treats osteoarticular infections of prosthetic joints caused by Staphylococcus aureus.
ACD Pharma is constructing a large-scale phage production plant.
Paper: Staphylococcal phages adapt to new hosts by extensive attachment site variability — Helena Leinweber et al.
Paper: A new sugar for an old phage: a c-di-GMP-dependent polysaccharide pathway sensitizes Escherichia coli for bacteriophage infection — Benjamin Sellner et al.
Paper: Isolation and characterization of Campylobacter jejuni–specific bacteriophages from Germany and their suitability for use in food production — Severin Michael Steffan et al.